On the protease gene, no major mutation was detected. However, many minor mutations, feature of the non B strains, were present and the most important.

Slides:



Advertisements
Similar presentations
1 Severe morbidity among HIV- infected patients : a comparison between a Brazilian and a French clinic based observational cohort FIOCRUZ: Prof B Grinsztejn.
Advertisements

Human rhinovirus species occurrence among adults with respiratory tract infection and asymptomatic individuals during two consecutive winter seasons Zlateva.
HIV-1 pol diversity and drug resistance mutations among female bar and hotel workers in Northern Tanzania Ireen Kiwelu Kilimanjaro International PhD symposium.
An epidemic in transition: impacts of migration and local networks on HIV sequence diversity and infection transmission in Australia
Monitoring the emergence of resistance mutations in patients under salvage therapy with Raltegravir in Rio de Janeiro, Brazil: a six month follow-up Caroline.
Tuberculosis incidence and risk factors among adult patients receiving HAART in Senegal: a 7-year cohort study Assane DIOUF et al. IRD/UMR 145 CRCF, CHNU.
The hidden HIV epidemic: what do mathematical models tell us? The case of France Virginie Supervie, Jacques Ndawinz & Dominique Costagliola U943 Inserm.
Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,
HIV AND HIV MUTANTS E. Chigidi and E. Lungu University of Botswana Private Bag 0022 Gaborone, Botswana.
PROMISE Introduction to PROMISE Protocol May 6, 2009.
Late HIV Diagnoses, Georgia,
6/28/00TPED1 Resistance Testing: What is it? What does it mean? How does drug resistance emerge? Overview of methods Advantages and disadvantages Current.
Celera and the Virus Celera and the Virus A review of current prospects of Applera SoCalBSI 2004 Timothy Ng 07/07/04.
H1N1: “Swine Flu”. Why you should care… Every year between 5 and 20% of the population gets the flu. The CDC estimates that the flu kills 36,000 people.
Persisting long term benefit of genotypic guided treatment in HIV infected patients failing HAART and Importance of Protease Inhibitor plasma levels. Viradapt.
HIV Drug Resistance Impact on ART for the Pregnant Woman Elliot Raizes, MD CDC Division of Global HIV/AIDS June 18, 2012.
Using Phylogenetic Analysis to Identify HIV Transmission Channels among Persons Newly Diagnosed with HIV-1 Infection in Los Angeles County, Kwa.
Phylogenetic Insight into HIV Transmission Networks in a Southeastern US Cohort Ann Dennis 1, Stéphane Hué 2, Christopher Hurt 1, Sonia Napravnik 1, Deenan.
Global HIV Resistance: The Implications of Transmission
Summary Slide Presentation Are subtype differences important in HIV drug resistance? Lessells RJ, Katzenstein DK, de Oliveira T. Are subtype differences.
Natural polymorphisms in the protease of HIV-1 isolates explain hypersusceptibility to protease inhibitors A.F. Santos, D.M. Tebit, M.S. Lalonde, A. Ratcliff,
Phylogenetic analysis of HIV-1 Gag cleavage sites polymorphism in HIV acutely infected patients Castro E 1,2, Cavassini M 1, Bart PA 2 and Pantaleo G 2.
Molecular genetics of HIV-1 strains spreading in Russia Edward Karamov Ivanovsky Institute of Virology, Moscow 4th World Congress on Virology, 6-8 October.
Dr Gilles Raguin, on behalf of ESTHER Senegal, IAS, 2012 HIV Prevention, treatment and care for IDUs in Senegal: An innovative ESTHER partnership.
Linking HIV-1 and Antiretroviral Drug Resistance Surveillances: Low Prevalence of HIV-1 Drug Resistance in Peru Lama JR 1, Suarez L 2, Laguna A 3, Acuña.
Antiretroviral Treatment Monitoring: A Canadian Case Example Antiretroviral Treatment Monitoring: A Canadian Case Example Robert Hogg, PhD BC Centre for.
1 ARV Drug Resistance HAIVN Harvard Medical School AIDS Initiative in Vietnam.
EARLY CHILDHOOD OUTCOMES AT THE BOTSWANA- BAYLOR CHILDREN’S CLINICAL CENTRE OF EXCELLENCE: A REPORT TO THE WHO TECHNICAL REFERENCE GROUP ON PEDIATRIC CARE.
Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.
Phylodynamically Estimated HIV Diversification Rates Reveal Prevention of HIV-1 by Antiretroviral Therapy Jeffrey B. Joy, Richard H. Liang, Rosemary M.
Immigration Removal Centres and HIV Clinical Care Jane Anderson Homerton University Hospital NHS Foundation Trust.
CASO CLINICO Il paziente naϊve ad alta viremia Rapido sviluppo di resistenza ad EFV dopo solo 4 mesi di terapia.
The WHO HIV Drug Resistance Strategy Presented by Dr. Don Sutherland Prepared by: Dr. Don Sutherland Dr Silvia Bertagnolio Dr Diane Bennett HIV Drug Resistance.
How Does Antiretroviral Therapy Affect HIV Mutation and Vice Versa? Arlin Toro Devin Iimoto Devin Iimoto.
Epidemiology of non-B clade forms of HIV-1 in MSM in the UK Fox J 1, Duda A 2,Green H 3, Dunn D 3, Kaye S 1, McClure M 1, Fidler S 1 Division of Medicine,
The Effectiveness of generic Highly Active Antiretroviral Therapy for the treatment of HIV infected Ugandan children Presenter: Linda Barlow-Mosha MD,
12th Conference on Retroviruses and Opportunistic Infections February 22-25, 2005 Boston, Massachusetts, USA Poster No. 830 Hematological Benefit of Switching.
High Discordance in Plasma and Genital Tract HIV-1 Drug Resistance in Indian Women Failing First-line Therapy MOPDA0106 S. Saravanan, PhD Session Code:
Source: EPP/Spectrum HIV estimates, EPHI, 2014 HAART is the recommended form of treatment HAART is usually combination of at least 3 drugs 2 NRTIs +
Drug Resistance Reports
Rationale and Uses For a Public HIV Drug Resistance Database Bob Shafer, MD Professor of Medicine and by Courtesy Pathology (Infectious Diseases)
Treatment Failure HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Phar. Nhat Mang/ Roche Vietnam
1/11/01 Pediatric trials for ARV experienced children Coleen K. Cunningham Epidemiology of treatment experience in pediatrics How does the smaller number.
Evolution and transmission in HIV Steve Paterson Review; Rambaut 2004 Nature Reviews Genetics 5: ‘The causes and consequences of HIV evolution’
Serologic markers and molecular epidemiology of HBV from an HIV infected cohort from Cameroon Tshifhiwa Magoro 1, Emmaculate Nongpang 2, Lufuno Mavhandu.
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection The INSIGHT START Study Group Ben Andres Oct 15, 2015.
Assessment of Genetic Diversity and drug resistance mutations to current classes of inhibitors circulating in HIV -1 infected individuals in Nigeria Negedu-momoh,
Date of download: 6/27/2016 Copyright © 2016 American Medical Association. All rights reserved. From: HIV-1 Drug Resistance Profiles in Children and Adults.
Dawit Assefa Ethiopia Health and Nutrition Research Institute Dawit Assefa Ethiopia Health and Nutrition Research Institute Evaluation of an in-house HIV.
CORRELATION BETWEEN HIV-1 MOLECULAR CHARACTERISTICS AND RESPONSE TO HAART IN PEDIATRIC POPULATION FROM SAO PAULO, BRAZIL Cristina Mendes de Oliveira, Rosangela.
CONCLUSIONS New Jersey’s Emergency Department HIV testing sites report higher seroprevalence than non-ED testing sites. Since University Hospital began.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
First-Line Treatment of HIV Infection With Either NNRTI- or PI-Based Regimens Effective for Long-term Disease Control Slideset on: MacArthur RD, Novak.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
High prevalence of antiretroviral drug resistance among HIV-infected pregnant women in Buenos Aires, Argentina Zapiola 1, D.M. Cecchini 2, S. Fernandez.
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial
Chief, Laboratory of Molecular Virology, CBER, FDA
Qualitative detection of proviral-DNA of HIV-1 in infants to determine the efficacy of antiretroviral therapy in the prevention of vertical transmission.
Phylogenetic relationships of HIV-1 Pol RT strains
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
Background Results Methods Conclusion
Introduction Results Objectives Methods Conclusion Funding
T. M. Walker, M. Merker, T. A. Kohl, D. W. Crook, S. Niemann, T. E. A
Evolution and transmission in HIV
The 7th EAHSC Detection of human papillomavirus DNA in tumors from Rwandese breast cancer patients Dr. Habyarimana T1,2,3, Attaleb M1, Mazarati JB3, Bakri.
Dolutegravir in PEPFAR
Rapid Detection of HIV-1 subtype C Integrase resistance mutations by the Use of High-Resolution Melting Analysis Tendai Washaya BSc, Msc. Pre-PhD Student.
HVDRS STUDY RESISTANCE: WE CARE
Share your thoughts on this presentation with #IAS2019
Presentation transcript:

On the protease gene, no major mutation was detected. However, many minor mutations, feature of the non B strains, were present and the most important are: M36I, K20I/R/T, H69K, I13V, L63P/T/H/S/G, I93L, L10I/V, G16E and V77I. HIV-1 drug resistance among naives patients in Senegal Background HAART has dramatically improved survival and quality of life among people living with HIV and AIDS globally. However, drug resistant mutations of HIV are a great challenge to the benefits of HAART In Senegal, HAART is available in the capital city since 1998 and gradually in the decentralized settings since Secondary resistance can be compared with the rich countries. But, circulating of primary resistance is no studies. Conclusion ARV reduces morbidity and mortality of HIV infected patients but resistance can occur Risk of transmission of resistants virus This study showed an emergence of drug resistance strains in HIV naïve patients (2%). Resistance surveillance and genetic diversity study are necessary and strategies to preserve the first line drugs are needed.. Results Characteristic of population and strains 87 (83, 65%) of 104 patients, were women and 17 were men. Age is only known for 97 patients with an average of 32 years. The median of LTCD4 was of 562 cellules/mm3. Phylogenetic analysis showed a predominance of the recombinant CRF02_AG with 64 strains (61,5%) but also the presence of other strains : A(n=1), A3, (n=2), B (n=4), C (n=8), D’ (n=1), CRF06 (n=2), CRF11_cpx (n=2), of the recombinants unique CFR02/A3 (n=5), F/U (n=1), G/U/G (n=1) CRF36_cpx /CRF02_AG (n=2), U/ CRF02_AG (n=4), U/ CRF37_cpx (n=1), Methodology 104 naive HIV-1 patients were recruited in 2 main clinical care center in 2003, 2005 and 2007 In , they were chosen on the basis of a rate of LTCD4/mm3 superior or equal to 350. In 2007, criteria are TCD4 superior or equal to 500 and/or age under 25 years : a 1850 pb fragment including PR gene et 420 first AA of RT gene was amplified by a nested RT-PCR : nested RT-PCR was done separatly for PR and RT gene Références Derache A, Maiga A., et coll. Evolution of genetic diversity and drug resistance mutation HIV-1 among untreated patients from Mali Between PMID: Laurent C, Ngom Gueye NF, Ndour CT et coll. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1- infected adults. J Acquir Immune Defic Syndr Jan 1;38(1):14-7 Nicaise Ndembi, Awet Abraha, et coll. Molecular Characterization of Human Immunodeficiency Virus Type 1(HIV-1) and HIV-2 in Yaounde´, Cameroon: Evidence of Major Drug Resistance Mutations in Newly Diagnosed Patients Infected with Subtypes Other than Subtype B. CLINICAL MICROBIOLOGY, Jan. 2008, p. 177–184 Toni T, Masquelier B et coll. HIV-1 ANTIRETROVIRAL drug resistance in recently infected patients in Abidjan, Cote Ivoire: A 4- years survey PMID: Objectives - To analyze the presence of mutations associated to ARV among newly diagnosed immunocompetent HIV positive patients. - To study strains polymorphism in both Protease (PR) and RT gene Detection of drug resistance mutations On RT gene, 1 sample presents major mutation (G190E) conferred a high level resistance to EFV and NVP. Ten samples present minor resistance mutations of which 4 associated to the NRTIs, 2 (E44D, V108I, K238KN and T215ST) and 6 to the non nucleoside (V179E, T69PT, K103EK, E138A A62V and V118I). According to the Stanford the K238N and the K103EK conferred an intermediate resistance to the DLV and the NVP. The T215ST conferred an intermediate resistance to the ZDV and the D4T.. Figure 2: Phylogenetic tree of 2005 Table 2: Drug resistance mutations on RT gene 2005 Acknowledgments ANRS 1257 financial project ANRS financial project Contact : Figure 3: Phylogénétic tree Figure 1: Characterization of strains A: 2005 B: Table 3: Drug resistance mutations on RT gene of Figure 4 : Drug resistance mutations on PR gene 2008 Leye N. 1, Diop-Ndiaye H. 1, Kebe K. 1, Guindo P.M. 1, Watara B. 3, Ngom Guèye N.F. 2, Diouf E B 2.., Diallo S. 1, Diop-Diongue O. 1, Diaw-Diouf N.A. 1, Gaye-Diallo A. 1, Sembène M. 3, Touré-Kane C 1. and Mboup S. 1 1 Laboratory Bactériology-Virology, University of Dakar N. 3, - 2 CTA OPALS, CHU de Fann, Sénégal- 3 Center of halth of Roi Baudouin Phylogenetic analysis were done by neighbour-joining method and sequences were submitted on Stanford HIVdb and were compared with the ANRS v and Rega v6.4.1algorithms and the IAS Resistance Testing-USA panel (09/2007) ERxample of set of primers used for the long fragment and the DNA analyzer : Applied Biosystems 3100 Avent Viral Check Workshop 21 th -27 th June Dakar Senegal